Italy
2.7researchedThe most capital-friendly ownership regime of the southern markets, capital companies have been able to own pharmacies since 2017, paired with the hardest operational barrier: Rx mail order is flatly prohibited and dematerialised e-prescriptions have not changed that. A workable business here is click-and-mortar, not remote fulfilment.
- Population
- 59m
- Currency
- EUR
- Region
- Southern Europe
- Updated
- 2026-08-23
The six axes
Five is always better for an operator. Hover a label for the question it answers.
How it works here
Ownership since 2017 [1]
Legge 124/2017, the Legge Concorrenza, allowed capital companies (s.r.l., s.p.a., s.a.p.a.) and non-pharmacist shareholders to own pharmacies alongside individual pharmacists, partnerships and cooperatives. Two limits apply: "la direzione di una farmacia gestita da una società deve essere comunque affidata a un farmacista", a qualified pharmacist must direct each pharmacy regardless of ownership, and a single company may hold, directly or indirectly, no more than 20% of the pharmacies in any one region.
That regional anti-concentration cap has no equivalent in Spain (no corporate ownership at all) or Portugal (a flat four-pharmacy national cap).
E-prescriptions changed the format, not the channel [1][2]
Fully dematerialised prescriptions became mandatory nationwide through the 2025 budget-law reforms, with multi-factor authentication requirements added and stabilised via the Milleproroghe 2026 decree. This is the point a founder must not misread: dematerialisation changes only whether the prescription is paper, not where the medicine can be bought. Distance sale of Rx-required medicines remains prohibited, and the medicine must still be purchased at a licensed pharmacy; only post-purchase home delivery is permitted under specific pharmacy arrangements.
Reimbursement, pricing and enforcement [1][2][3]
AIFA added tirzepatide to Nota 100 for type 2 diabetes effective 23 February 2025; semaglutide is likewise reimbursed for diabetes only. Obesity is fully private, with Wegovy reported around €300–400/month at maintenance and Mounjaro €300–500 depending on dose.
On enforcement: in December 2025 AGCM fined Talea Group S.p.A. (Farmaè, Amicafarmacia) €2 million for unfair commercial practices, fictitious availability, delayed deliveries and refunds. That is not GLP-1-advertising-specific but shows active regulatory attention on the online-pharmacy sector. Polizia Postale has blocked dozens of illegal medicine sites, and Italy seized close to 20,000 packages in the international Pangea 2026 operation.
Several Italian-language sites openly advertise Wegovy and Mounjaro "senza ricetta". Given the statutory ban, treat those as grey-market operations, not comparators.
Who is already there
| Name | Model | Price |
|---|---|---|
| Serenis | Established Italian telehealth platform publishing extensive GLP-1 content; whether it prescribes or only markets is unconfirmed | n/a |
| Theia | Bologna-based telehealth and nutrition service publishing GLP-1 access guides | n/a |
| Specialist obesity clinics | The dominant real-world channel, endocrinology and obesity-medicine practices rather than pure-play DTC, plausibly a direct consequence of the mail-order ban | n/a |
Routes in, and walls
What works viable
- Establish a capital company owning pharmacies with employed pharmacist-directors, respecting the 20% regional cap.
- Pair a telehealth triage front end with a network of prescribing specialists and physical collection at a licensed pharmacy, genuine click-and-mortar.
What does not blocked
- Cross-border or domestic mail-order dispensing of Rx GLP-1s. Explicitly illegal and actively enforced.
- Consumer advertising naming the product, under art. 115.
- Assuming mandatory e-prescriptions opened a path to remote dispensing. They did not.
How to make it work
The recommended entry path for a non-pharmacist operator running an own brand with a partner pharmacy. Read it against the six axes above, not instead of them.
Telehealth triage front end plus prescribing specialists and physical collection at a licensed pharmacy.
Capital companies can own pharmacies subject to a 20 per cent regional cap, so ownership is possible but constrained. Mail order for prescription medicines barely functions and advertising room is minimal, so this is a genuine click-and-mortar market rather than a digital one.
- Decide whether to own within the 20 per cent regional cap or simply partnerPartnering is faster and the cap makes national scale through ownership impractical.
- Build the triage layer and a network of prescribing specialistsThe specialist relationship is what unlocks the market.
- Design for in-person collectionDo not build a mail-order thesis here.
Advertising room of 1 out of 5 and no working mail order, so both ends of the funnel are constrained.
Moderate. Better as a later market.
What has happened
What we could not establish
Kept visible on purpose. These are the gaps a decision would have to close.
- Does ZAVA or another major pan-European brand formally operate an Italian storefront?
- Has AIFA or AGCM taken enforcement specifically against GLP-1 advertising, as distinct from general online-pharmacy practices?
- Exactly when in 2025 did non-reimbursed Wegovy sale begin in Italy?
Sources
Every non-obvious claim above links here. Confidence tags are applied strictly.
Read next
Who can own a pharmacy
The single structural fact that decides whether you can own the margin or only rent it, and it varies more across Europe than anything else in this atlas.
topicRedcare Pharmacy
The pharmacy that lost the Zava case, and is running the Zava referral again today from its own product pages.
companyDocMorris
A pharmacy that owns its own prescriber, which is the exact structure §11 ApoG exists to prevent, and it lost on that point in April 2026.
company